secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0000950170-23-064005
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes completes spin-off of oncology business into Mural; raises 2023 guidance
--------------------------------------------------------------------------------

- On Nov 15, 2023, distributed 1 Mural share for every 10 Alkermes shares; MURA begins trading Nov 16.
- FY2023 GAAP net income guidance raised to $250M–$280M from $225M–$265M; diluted EPS $1.46–$1.63.
- Non-GAAP net income guidance raised to $270M–$300M from $230M–$270M; diluted EPS $1.57–$1.75.
- Alkermes capitalized Mural with $275M cash; now a pure-play neuroscience company.
- Operating expenses expected to drop ~$20M in last six weeks of 2023 due to separation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023064005/0000950170-23-064005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023064005/alks-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-064005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer